19-Apr-2024
Analysts’ Top Healthcare Picks: Elevance Health (ELV), Argenx Se (ARGX)
TipRanks (Fri, 19-Apr 5:50 AM ET)
As more rare disease therapies launch, their prices are rising
Seeking Alpha News (Tue, 16-Apr 12:22 PM ET)
Business Wire (Thu, 7-Mar 4:01 PM ET)
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
Business Wire (Mon, 26-Feb 9:00 AM ET)
Business Wire (Thu, 22-Feb 8:30 AM ET)
Business Wire (Tue, 20-Feb 9:00 AM ET)
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
Arcturus Therapeutics Holdings trades on the NASDAQ stock market under the symbol ARCT.
As of April 19, 2024, ARCT stock price declined to $25.98 with 599,353 million shares trading.
ARCT has a beta of 2.45, meaning it tends to be more sensitive to market movements. ARCT has a correlation of 0.21 to the broad based SPY ETF.
ARCT has a market cap of $699.26 million. This is considered a Small Cap stock.
Last quarter Arcturus Therapeutics Holdings reported $34 million in Revenue and -$.32 earnings per share. This fell short of revenue expectation by $-4 million and exceeded earnings estimates by $.67.
In the last 3 years, ARCT stock traded as high as $65.00 and as low as $11.70.
The top ETF exchange traded funds that ARCT belongs to (by Net Assets): ARKG, XBI, VTI, IWM, VXF.
ARCT has underperformed the market in the last year with a price return of -6.8% while the SPY ETF gained +21.2%. ARCT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -19.5% and -15.1%, respectively, while the SPY returned +4.3% and -3.5%, respectively.
ARCT support price is $25.11 and resistance is $27.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARCT stock will trade within this expected range on the day.